JP2025511403A5 - - Google Patents
Info
- Publication number
- JP2025511403A5 JP2025511403A5 JP2024559036A JP2024559036A JP2025511403A5 JP 2025511403 A5 JP2025511403 A5 JP 2025511403A5 JP 2024559036 A JP2024559036 A JP 2024559036A JP 2024559036 A JP2024559036 A JP 2024559036A JP 2025511403 A5 JP2025511403 A5 JP 2025511403A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263362614P | 2022-04-07 | 2022-04-07 | |
| US63/362,614 | 2022-04-07 | ||
| PCT/EP2023/059123 WO2023194525A1 (en) | 2022-04-07 | 2023-04-06 | Combination therapy for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025511403A JP2025511403A (ja) | 2025-04-15 |
| JP2025511403A5 true JP2025511403A5 (https=) | 2026-04-10 |
| JPWO2023194525A5 JPWO2023194525A5 (https=) | 2026-04-10 |
Family
ID=86184958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559036A Pending JP2025511403A (ja) | 2022-04-07 | 2023-04-06 | 癌を治療するための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250228847A1 (https=) |
| EP (1) | EP4504147A1 (https=) |
| JP (1) | JP2025511403A (https=) |
| KR (1) | KR20240170958A (https=) |
| CN (1) | CN118973555A (https=) |
| AU (1) | AU2023250030A1 (https=) |
| CA (1) | CA3254950A1 (https=) |
| IL (1) | IL316019A (https=) |
| MX (1) | MX2024012369A (https=) |
| TW (1) | TW202404592A (https=) |
| WO (1) | WO2023194525A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0705903B2 (en) | 1994-08-12 | 2009-08-12 | The University of Utah Research Foundation | Mutations in the 17q-linked breast and ovarian cancer susceptibility gene |
| DK0699754T3 (da) | 1994-08-12 | 2001-02-26 | Myriad Genetics Inc | Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer |
| WO2018191141A1 (en) * | 2017-04-13 | 2018-10-18 | Janssen Pharmaceutica Nv | Combination therapy for prostate cancer |
| MX2022000711A (es) | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
| TW202228693A (zh) * | 2020-10-08 | 2022-08-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
-
2023
- 2023-04-06 WO PCT/EP2023/059123 patent/WO2023194525A1/en not_active Ceased
- 2023-04-06 IL IL316019A patent/IL316019A/en unknown
- 2023-04-06 KR KR1020247036945A patent/KR20240170958A/ko active Pending
- 2023-04-06 JP JP2024559036A patent/JP2025511403A/ja active Pending
- 2023-04-06 AU AU2023250030A patent/AU2023250030A1/en active Pending
- 2023-04-06 US US18/853,520 patent/US20250228847A1/en active Pending
- 2023-04-06 CN CN202380032506.8A patent/CN118973555A/zh active Pending
- 2023-04-06 EP EP23719306.5A patent/EP4504147A1/en active Pending
- 2023-04-06 CA CA3254950A patent/CA3254950A1/en active Pending
- 2023-04-07 TW TW112112998A patent/TW202404592A/zh unknown
-
2024
- 2024-10-04 MX MX2024012369A patent/MX2024012369A/es unknown